National Institute on Drug Abuse; Notice of Closed Meetings, 11926-11927 [2023-03846]
Download as PDF
<![CDATA[
11926
Federal Register / Vol. 88, No. 37 / Friday, February 24, 2023 / Notices
Dated: February 17, 2023.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–03848 Filed 2–23–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
ddrumheller on DSK120RN23PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Cell and Molecular Biology.
Date: March 21–22, 2023.
Time: 9:30 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Megan Lynne Goodall,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 594–8334, megan.goodall@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Social and Community Influences
Across the Life Course.
Date: March 21, 2023.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Shahrzad Mavandadi,
Ph.D., Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, 301–496–4792,
shahrzad.mavandadi@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Social and Community Influences
Across the Life Course.
Date: March 22–23, 2023.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Sep<11>2014
18:15 Feb 23, 2023
Jkt 259001
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: David Erik Pollio, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1006F,
Bethesda, MD 20892, (301) 594–4002,
polliode@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Digestive Sciences.
Date: March 24, 2023.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Ganesan Ramesh, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2182,
MSC 7818, Bethesda, MD 20892, 301–827–
5467, ganesan.ramesh@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Medical Imaging Investigations.
Date: March 24, 2023.
Time: 9:30 a.m. to 9:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Zheng Li, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Bethesda, MD 20892, (301) 594–3385,
zheng.li3@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Mobile
Health, Technologies and Outcomes in Low
and Middle Income Countries—HIV/AIDS
and Sexual Health Applications.
Date: March 24, 2023.
Time: 9:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Abu Saleh Mohammad
Abdullah, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Room 1003–L, Bethesda, MD 20892, (301)
827–4043, abuabdullah.abdullah@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Understanding Alzheimer’s
Degeneration and the Related Dementia.
Date: March 24, 2023.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Alena Valeryevna
Savonenko, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Room 1009J, Bethesda, MD 20892, (301) 594–
3444, savonenkoa2@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Topics in
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
Autoimmunity, Immunology, and
Transplantation.
Date: March 24, 2023.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Shannon J. Sherman,
Ph.D., Scientific Review Officer, The Center
for Scientific Review, The National Institutes
of Health, 6701 Rockledge Drive, Bethesda,
MD 20892, 301–594–0715,
shannon.sherman@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Macromolecular Biophysics and
Biological Chemistry.
Date: March 24, 2023.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Nuria E. Assa-Munt, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4164,
MSC 7806, Bethesda, MD 20892, (301) 451–
1323, assamunu@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 17, 2023.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–03850 Filed 2–23–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
E:\FR\FM\24FEN1.SGM
24FEN1
ddrumheller on DSK120RN23PROD with NOTICES
Federal Register / Vol. 88, No. 37 / Friday, February 24, 2023 / Notices
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Mechanism for Time-Sensitive Drug Abuse
Research.
Date: March 20, 2023.
Time: 12:00 p.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sudhirkumar Udhavrao
Yanpallewar, M.D., Scientific Review Officer,
Scientific Review Branch, National Institute
on Drug Abuse, NIH, 301 North Stonestreet
Avenue, Bethesda, MD 20892, (301) 443–
4577, sudhirkumar.yanpallewar@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; HEAL
Initiative: HEAL Data2Action—Innovation
and Acceleration Projects, Phased Awards.
Date: March 22, 2023.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Trinh T. Tran, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, Bethesda, MD 20892,
(301) 827–5843 trinh.tran@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Registry
of Medical Cannabis Use and Health
Outcomes.
Date: March 24, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, Bethesda, MD 20892,
(301) 827–5819, gm145a@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Omnibus Topic 167: Cause of Death
Elucidated (CODE) in Drug Overdose:
Research and Development of New
Postmortem Toxicology Screening Devices
That Are Portable, Rapid, Accurate,
Affordable, and Accessible.
Date: March 30, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, Bethesda, MD 20892,
(301) 827–5819, gm145a@nih.gov.
VerDate Sep<11>2014
18:15 Feb 23, 2023
Jkt 259001
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: February 17, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–03846 Filed 2–23–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice To Announce Updated Minimum
Performance Standards for
Experienced Firms That Receive
Funding Through the Small Business
Innovation Research (SBIR) and Small
Business Technology Transfer (STTR)
Programs
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institutes of
Health (NIH) announces the updated
minimum performance standards for
experienced firms funded through the
Department of Health and Human
Services (HHS) Small Business
Innovation Research (SBIR) and Small
Business Technology Transfer (STTR)
Programs.
DATES: The relevant funding
opportunity announcements have been
updated to incorporate these changes.
The updated performance standards
will be required of any firms submitting
SBIR or STTR grant or cooperative
agreement applications on or after April
5, 2023.
ADDRESSES: Please visit our website to
view the updated Minimum
Performance Standards for Experienced
Firms at https://seed.nih.gov/smallbusiness-funding/small-businessprogram-basics/eligibility-criteria.
FOR FURTHER INFORMATION CONTACT:
Stephanie Fertig, HHS Small Business
Program Lead, Small business
Education & Entrepreneurial
Development (SEED) Office, Office of
Extramural Research, NIH, Rockledge I,
Suite 800, Bethesda, MD 20817. Email:
seedinfo@nih.gov. Phone number (301)
435–2688.
SUPPLEMENTARY INFORMATION: The new
minimum standards are aligned with
Section 9 of the Small Business Act (15
SUMMARY:
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
11927
U.S.C. 638), as amended by the SBIR
and STTR Extension Act of 2022 (Pub.
L. 117–183).
HHS is announcing the following
changes:
Phase I to Phase II Transition Rate
Benchmark: In accordance with
guidance from the SBA, the HHS SBIR/
STTR Program is implementing the
Phase I to Phase II Transition Rate
benchmark required by the SBIR/STTR
Reauthorization Act of 2011 and the
SBIR and STTR Extension Act of 2022.
The benchmark establishes a minimum
number of Phase II awards the company
must have received for a given number
of Phase I awards received during the 5year time period. The Transition Rate is
calculated as the total number of SBIR
and STTR Phase II awards a company
received during the past 5 fiscal years
divided by the total number of SBIR and
STTR Phase I awards it received during
the past 5 fiscal years excluding the
most recently-completed year.
Phase II to Commercialization
Benchmark: In accordance with
guidance from the SBA, HHS, including
NIH, SBIR/STTR Programs are
implementing the Phase II to
Commercialization Rate benchmark for
Phase I applicants, as required by the
SBIR/STTR Reauthorization Act of 2011
and the SBIR and STTR Extension Act
of 2022. The Commercialization Rate
Benchmark was published in a Federal
Register notice on August 8, 2013 (78
FR 48537).
This update is applicable to all HHS
SBIR and STTR grants and cooperative
agreements with application receipt
dates on or after April 5, 2023. This
update supersedes, in its entirety,
previous Phase I to Phase II transition
benchmarks established in May 2013
(78 FR 30951) and previous
Commercialization Benchmarks
established in September 2013 (78 FR
59410). Additional information can be
found at: https://grants.nih.gov/grants/
guide/notice-files/not-od-23-092.htm.
Dated: February 16, 2023.
Tara A. Schwetz,
Acting Principal Deputy Director, National
Institutes of Health.
[FR Doc. 2023–03798 Filed 2–23–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Library of Medicine; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
E:\FR\FM\24FEN1.SGM
24FEN1
]]>Agencies
[Federal Register Volume 88, Number 37 (Friday, February 24, 2023)]
[Notices]
[Pages 11926-11927]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-03846]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
[[Page 11927]]
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Mechanism for Time-Sensitive Drug Abuse Research.
Date: March 20, 2023.
Time: 12:00 p.m. to 1:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sudhirkumar Udhavrao Yanpallewar, M.D.,
Scientific Review Officer, Scientific Review Branch, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
Bethesda, MD 20892, (301) 443-4577, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; HEAL Initiative: HEAL Data2Action--Innovation and
Acceleration Projects, Phased Awards.
Date: March 22, 2023.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Trinh T. Tran, Ph.D., Scientific Review Officer,
Scientific Review Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
Bethesda, MD 20892, (301) 827-5843 [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Registry of Medical Cannabis Use and Health
Outcomes.
Date: March 24, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, NIH, 301 North Stonestreet Avenue, Bethesda, MD
20892, (301) 827-5819, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Omnibus Topic 167: Cause of Death Elucidated (CODE)
in Drug Overdose: Research and Development of New Postmortem
Toxicology Screening Devices That Are Portable, Rapid, Accurate,
Affordable, and Accessible.
Date: March 30, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, NIH, 301 North Stonestreet Avenue, Bethesda, MD
20892, (301) 827-5819, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: February 17, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-03846 Filed 2-23-23; 8:45 am]
BILLING CODE 4140-01-P
